Gilead announced it would charge between $2,340 and $3,120 for a 5-day course of its COVID-19 drug remdesivir, BioPharma Dive reports.
According to the report, Gilead plans to offer the drug to the governments in developed countries with a price tag of $390 per vial. Private entities and some government programs in the U.S. will pay $520 per vial.
“Our work on remdesivir is far from done,” Gilead Chairman and CEO Daniel O’Day said in a statement. “We continue to explore its potential to help in this pandemic in various ways, such as evaluating treatment earlier in the course of the disease, in outpatient settings, with an inhaled formulation, in additional patient groups and in combination with other therapies.”
To read BioPharma Dive’s report, click here.
Click here to read O’Day’s full statement on Gilead’s website.